Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK4 | Q16654 | 1/20 | 0.60 |
| ▸ | NAMPT | P43490 | 1/20 | 0.59 |
| ▸ | GRM5 | P41594 | 9/20 | 0.57 |
| ▸ | GRM1 | Q13255 | 9/20 | 0.57 |
| ▸ | HTR6 | P50406 | 1/20 | 0.53 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.48 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19989639 | 0.92 | NAMPT (0.67) | PDK4NAMPTGRM5GRM1HTR6 | |
| SCHEMBL2239831 | 0.92 | NAMPT (0.66) | PDK4NAMPTGRM5GRM1HTR6 | |
| SCHEMBL2954198 | 0.90 | NAMPT (0.54) | PDK4NAMPTGRM5GRM1CYP11B2 | |
| SCHEMBL4459006 | 0.90 | PDK4 (0.54) | PDK4NAMPTGRM5GRM1HTR6 | |
| SCHEMBL7831576 | 0.89 | PDK4 (0.58) | PDK4NAMPTGRM5GRM1HTR6 | |
| SCHEMBL3169756 | 0.88 | PDK4 (0.55) | PDK4NAMPTGRM5GRM1HTR6 | |
| SCHEMBL29914645 | 0.88 | PDK4 (0.57) | PDK4NAMPTGRM5GRM1HTR6 | |
| SCHEMBL1364792 | 0.88 | PDK4 (0.57) | PDK4NAMPTGRM5GRM1HTR6 | |
| SCHEMBL7939636 | 0.88 | PDK4 (0.55) | PDK4NAMPTGRM5GRM1HTR6 | |
| SCHEMBL902871 | 0.87 | PDK4 (0.56) | PDK4NAMPTGRM5GRM1HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250026749-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORPORATION (US) | 2025-01-23 | — | — | US | disclosed |
| US-12060349-B2 | Glucosylceramide synthase inhibitors | GENZYME CORPORATION (US) | 2024-08-13 | — | — | US | disclosed |
| EP-4098654-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | Genzyme Corporation (US) | 2022-12-07 | — | — | EP | disclosed |
| US-20220073508-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORPORATION (US) | 2022-03-10 | — | — | US | disclosed |
| EP-2895484-B1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORP (US) | 2022-02-23 | — | — | EP | disclosed |
| US-11008316-B2 | Glucosylceramide synthase inhibitors | GENZYME CORPORATION (US) | 2021-05-18 | — | — | US | disclosed |
| US-20180065957-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORPORATION (US) | 2018-03-08 | — | — | US | disclosed |
| US-20150210681-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORPORATION (US) | 2015-07-30 | — | — | US | disclosed |
| EP-2895484-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | Genzyme Corporation (US) | 2015-07-22 | — | — | EP | disclosed |
| WO-2014043068-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORPORATION (US) | 2014-03-20 | — | — | WO | disclosed |
| EP-1689712-B1 | 4-PHENYLPIPERIDINE DERIVATIVES AS RENIN INHIBITORS | NOVARTIS AG (CH) | 2009-08-19 | — | — | EP | disclosed |
| EP-1996550-A2 | CARBOXYAMINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF HDAC DEPENDENT DISEASES | Novartis AG (CH) | 2008-12-03 | — | — | EP | disclosed |
| US-20080269255-A1 | 4-Phenylpiperidine Derivatives as Renin Inhibitors | NOVARTIS AG (CH) | 2008-10-30 | — | — | US | disclosed |
| US-20080255149-A1 | Carboxyamine Compounds and Methods of Use Thereof | NOVARTIS AG | 2008-10-16 | — | — | US | disclosed |
| US-20080255149-A1 | Carboxyamine Compounds and Methods of Use Thereof | NOVARTIS AG | 2008-10-16 | — | — | US | disclosed |
| US-20080255149-A1 | Carboxyamine Compounds and Methods of Use Thereof | NOVARTIS AG | 2008-10-16 | — | — | US | disclosed |
| US-20070078164-A1 | 4-Phenylpiperidine derivatives as renin inhibitors | SEDRANI RICHARD | 2007-04-05 | — | — | US | disclosed |
| WO-2007038459-A2 | CARBOXYAMINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF HDAC DEPENDENT DISEASES | NOVARTIS AG (CH) | 2007-04-05 | — | — | WO | disclosed |
| WO-2007038459-A2 | CARBOXYAMINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF HDAC DEPENDENT DISEASES | NOVARTIS AG (CH) | 2007-04-05 | — | — | WO | disclosed |
| US-5712285-A | Pyrrolo-pyridine derivatives | MERCK, SHARP & DOHME, LTD. (GB) | 1998-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150210681-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GBA1, GBA2, GAA | PDK4 2731/4885NAMPT 312/4885GRM5 2726/4885 |
| US-20180065957-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GBA1, GBA2, GAA | PDK4 2731/4885NAMPT 312/4885GRM5 2726/4885 |
| US-11008316-B2 | Glucosylceramide synthase inhibitors | GBA1, GBA2, GAA | PDK4 2518/4885NAMPT 390/4885GRM5 2657/4885 |
| US-12060349-B2 | Glucosylceramide synthase inhibitors | GBA1, GBA2, GALC | PDK4 3819/4885NAMPT 407/4885GRM5 2129/4885 |
| US-20250026749-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GBA1, GBA2, GAA | PDK4 2731/4885NAMPT 312/4885GRM5 2726/4885 |
| US-20080255149-A1 | Carboxyamine Compounds and Methods of Use Thereof | HNMT, HDAC5, HDAC4 | PDK4 1004/4885NAMPT 217/4885GRM5 610/4885 |
| US-20080269255-A1 | 4-Phenylpiperidine Derivatives as Renin Inhibitors | REN, AGTR1, ACE | PDK4 362/4885NAMPT 3894/4885GRM5 2102/4885 |
| US-20070078164-A1 | 4-Phenylpiperidine derivatives as renin inhibitors | REN, AGTR1, ACE | PDK4 299/4885NAMPT 3783/4885GRM5 2403/4885 |
| US-20220073508-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GBA1, GBA2, GAA | PDK4 2731/4885NAMPT 312/4885GRM5 2726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.